TSX Exchange Symbol: RVX
CALGARY, Oct. 21 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX)
announced today that the ongoing double blind placebo controlled Phase 1b/2a
study in subjects with normal and low HDL is progressing as planned. The
subjects in the first group receiving a low dose of RVX-208 show safety and
tolerability. Thus the safety committee the has made a decision to commence
the next cohort in which 24 subjects will receive treatment doses escalating
each week, for a total of 4 weeks.
Donald J. McCaffrey, President and CEO of Resverlogix stated, "We are
very pleased to be able to share this exciting clinical information with the
Clinical Advisory Board at the American Heart Association meeting on
Resverlogix will give an oral presentation during the American Heart
Association Scientific Sessions meeting in November 2008 where the Company
will present novel data for RVX-208 to attendees. Due to the nature of double
blinded clinical trials and strict embargo rules set by the American Heart
Association, data from this Phase 1b/2a clinical trial will not be presented
in full until the completion of the trial.
RVX-208, a novel small molecule therapeutic that facilitates endogenous
ApoA-I production, is positioned to be one of the most promising emerging
drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208
is the only novel small molecule that is specifically designed to increase
ApoA-I production and thereby raise HDL levels thus enhancing HDL
functionality to augment reverse cholesterol transport (RCT).
RCT is a pathway by which accumulated cholesterol is transported from the
arterial wall to the liver for excretion, thus preventing atherosclerosis.
Major constituents of RCT include acceptors such as high-density lipoprotein
(HDL) and apolipoprotein A-I (ApoA-I). A critical part of RCT is cholesterol
efflux, in which accumulated cholesterol is removed from macrophages.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and
other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases, such
as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange
(TSX:RVX). For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp., Phone: (403) 254-9252, Fax: (403) 256-8495, Email:
Sarah@resverlogix.com; Website: www.resverlogix.com